


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
ATTORNEYS AT LAW
1100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934
PHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com



16000
RECEIVED
TECH CENTER
DEC 26 2001
FEB 21 2002
RECEIVED
328-02

ROBERT O'BRIEN STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX**
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG

JOHN M. COVERT
LINDA E. ALCORN
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
PATRICK E. GARRETT
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES

EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
VINCENT L. CAPUANO
JOHN A. HARROUN*
ALBERT J. FASULO II*
ELDORA ELLISON FLOYD*

W. RUSSELL SWINDELL
THOMAS C. FIALA
BRIAN J. DEL BUONO*
VIRGIL L. BEASTON*
RYAN J. STAMPER*
REGINALD D. LUCAS*
THEODORE A. WOOD
ELIZABETH J. HAANES
BRUCE E. CHALKER
JOSEPH S. OSTROFF
KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
ANDREA J. KAMAGE**

NANCY J. LEITH
JOSEPH M. CONNOR, III
DOUGLAS M. WILSON**
ANN E. SUMMERFIELD*
CYNTHIA M. BOHREZ**
HELENE C. CARLSON**
GABY L. LONGEVORTH
DUSTIN T. JOHNSON**
MATTHEW J. DOWNS**
AARON L. SCHWARTZ**

*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

December 17, 2001

Commissioner for Patents
Washington, D.C. 20231

WRITER'S DIRECT NUMBER:
(202) 371-2560
INTERNET ADDRESS:
RESMOND@SKGF.COM

Attn: Office of Initial Patent
Examination's Customer
Service Center

Re: U.S. Utility Patent Application
Appl. No. 09/964,666; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for
the Treatment or Prevention of Alzheimer's Disease**
Inventors: de la Monte *et al.*
Our Ref: 0609.4370003/RWE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Response to Request for Corrected Filing Receipt;
2. Request for Corrected Official Filing Receipt;
3. A photocopy of the instant Official Filing Receipt with corrections noted in red;
4. A copy of Substitute Application Data Sheet (previously filed on November 30, 2001); and
5. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 17, 2001
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE/MJC/lam
Enclosures

P:\USERS\MCRONIN\0609.4370003\pto\resubmissionofrcorrectionptotrn

EC 2 6 2001



UNITED STATES PATENT AND TRADEMARK OFFICE


TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/964,666	09/28/2001	Suzanne De La Monte	0609.4370003

26111
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, DC 20005-3934

CONFIRMATION NO. 3650



Date Mailed: 12/23/2001

RESPONSE TO REQUEST FOR CORRECTED FILING RECEIPT

Application Filing Date

In response to your request for a corrected Filing Receipt, the Office is unable to comply with your request because:

- ☐ The correct application number appears on the Filing Receipt. Your postcard included an incorrect application number. Please update your records to reflect the application number on the enclosed Filing Receipt. See MPEP 503.
- ☐ If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, a request for a corrected Filing Receipt should be submitted along with a copy of the Express Mail label showing the "date in."
- ☐ A copy of the Express Mail label was not enclosed with your request. Please resubmit.
- ☐ The date on the Express Mail label is the date given on the Filing Receipt.
- ☐ The filing date accorded to the application is the date the application met the filing date requirements of 37 CFR 1.53(b) or (c).
- ☒ Filing date of a parent application cannot be changed by this request. A request for corrected Filing Receipt must be directed to such parent application.
- ☐ Applications submitted under 37 CFR 1.8 are accorded a filing date as of the date the application is received in the U.S. Patent and Trademark Office.
- ☐ The filing date on your return postcard is the same as the date on your Filing Receipt.


A petition under 37 CFR 1.10 or 1.53 is needed to correct the filing date. The petition should be

☐ directed to the attention of the Office of Petitions.


Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

A copy of this notice MUST be returned with the reply.



Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
DEC 26 2001
TECH CENTER 1600/2900

RECEIVED

In re application of:

de la Monte *et al.*

Appl. No. 09/964,666

Filed: September 28, 2001

For: **Transgenic Animals and
Cell Lines for Screening
Drugs Effective for the
Treatment or Prevention of
Alzheimer's Disease**

Confirmation No. 3650

Art Unit: 1633

Examiner: *To be assigned*

Atty. Docket: 0609.4370003/RWE

FEB 21 2002

TECH CENTER 1600/2900

Request for Corrected Official Filing Receipt

Commissioner for Patents
Washington, D.C. 20231

Attn: Office of Initial Patent
Examination's Customer
Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:


In the Domestic Priority data as claimed by applicant section at line 1, please delete "***"; and at line 4, please delete "(*) Data inconsistent with PTO records." Applicants submit that this data is correct. The claim to domestic priority in the Official Filing Receipt is correct, and consistent with the continuity information provided in the Substitute Application Data Sheet, which was filed on November 30, 2001. Applicants submit herewith a photocopy of the Substitute Application Data Sheet.

In the enclosed "Response to Request for Corrected Filing Receipt," the box is checked next to the statement "Filing date of a parent application cannot be changed by this request." However, Applicants are not requesting the change of the parent application filing date. Instead, Applicants are only asking that erroneous information be deleted from the filing receipt of the present application.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: Dec. 17, 2001
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

DEC 26 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2000

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP APP UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/964,666	09/28/2000	1633	870	0609.4370003	13	17	5

26111

 STERNE, KESSLER, GOLDSTEIN & FOX PLLC
 1100 NEW YORK AVENUE, N.W., SUITE 600
 WASHINGTON, DC 20005-3934

CONFIRMATION NO. 3650

FILING RECEIPT



OC000000007040579

Date Mailed 11/08/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)
 Suzanne De La Monte, East Greenwich, RI;
 Jack R. Wands, Waban, MA;
Domestic Priority data as claimed by applicant
 THIS APPLICATION IS A DIV OF 09/380,203 04/25/2000
 WHICH IS A 371 OF PCT/US98/03685 02/26/1998
 WHICH CLAIMS BENEFIT OF 60/038,908 02/26/1997

(*) Data inconsistent with PTO records.


Foreign Applications

If Required, Foreign Filing License Granted 11/07/2001

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

Title
 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of
 alzheimer's disease
Preliminary Class
 STERNE, KESSLER,
 GOLDSTEIN, FOX

 RWG
 MSC

11/13 MSC


RECEIVED

FEB 21 2002

RECEIVED

DEC 26 2001

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER****Title 35, United States Code, Section 184****Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).